​​ Read the beginning of the article There are many obvio | Dr Naomi R Wolf

​​ Read the beginning of the article
There are many obvious methodological problems that have already been identified with the study design, which mean it will likely fail to show efficacy. This will then be used as ‘primary evidence’ not to licence the drug. It is also a time-wasting exercise, in the knowledge that if an effective treatment is licensed, the Emergency Use Authorisations for the vaccines are invalidated.

The Indian Bar Association has issued a legal notice on the WHO in objection to its pressure on Indian states to discontinue the use of ivermectin during their recent surge. Meanwhile, some cardiotoxic drug regimes were used in trials throughout Europe during the first wave, including a trial in the UK using a dose of hydroxychloroquine tenfold the recommended level, a drug which when given early and in the correct dose may be beneficial but may indeed have led to increased deaths when given to patients already extremely sick and in doses well above those known to be potentially toxic.

The study design was signed off by the CMO (Chris Whitty). We urge the government and GPs to independently review the evidence around ivermectin and to critically evaluate whether this in fact offers a far safer alternative in the prevention of COVID-19 deaths than the experimental vaccines currently being rolled out.

Subscribe and share @naomirwolf